[Recombinant replication-defective adenovirus based rabies vaccine].
OBJECTIVE
To construct and characterize recombinant adenoviruses containing glycoprotein (GP) gene from rabies virus CVS-N2C strain.


METHODS
To obtain the recombinant adenovirus by pAdEasy system, identify recombinant virus with cDNA sequencing, Northern blot, Dot blot, Western blot and challenge-protection experiment of mice.


RESULTS
Recombinant adenovirus showed typical adenovirus morphological characteristics; the viral genome was stable; GP specific mRNA and presence of glycoprotein were determined in rAdGPcvs and rAdGPcvs' infected cells. The glycoprotein produced by recombinant adenovirus had a molecular mass of 66,000, which was similar to that of natural glycoprotein. In the group of rAdGPcvs immunized mice, 87.5%-100% of mice survived from a 35.8LD50/38.0LD50 lethal rabies intracerebral challenge. Finally 73.3%-83.3% of the mice that had received eAdGPcvs survived, and all the Ad5 immunized mice succumbed to rabies.


CONCLUSIONS
Recombinant adenovirus rAdGPcvs and rAdGPcvs' hold great potential to be developed as recombinant rabies vaccines, and at the same time, it is actually the first study that on high neuropathogenicity rabies CVS-N2C glycoprotein based adenoviral recombinants.
Li
Wen-hui
WH
Department of Etiology, Institute of Basic Medical Science, CAMS and PUMC, Beijing 100005, China.
Zhang
Yun
Y
Wang
Shu-hui
SH
Liu
Li
L
Yang
Fan
F
D017503:Adenovirus E3 Proteins / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology; D000260:Adenoviruses, Human / Q000235:genetics*; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology; D000956:Antigens, Viral; D001483:Base Sequence; D005822:Genetic Vectors; D006023:Glycoproteins / Q000096:biosynthesis* / Q000235:genetics / Q000276:immunology; D006801:Humans; D051379:Mice; D008969:Molecular Sequence Data; D009698:Nucleoproteins / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology; D011818:Rabies / Q000276:immunology / Q000517:prevention & control*; D011819:Rabies Vaccines / Q000096:biosynthesis* / Q000235:genetics / Q000276:immunology; D011820:Rabies virus / Q000235:genetics / Q000276:immunology; D014614:Vaccines, Synthetic / Q000096:biosynthesis* / Q000235:genetics / Q000276:immunology; D014759:Viral Envelope Proteins / Q000096:biosynthesis* / Q000235:genetics / Q000276:immunology; D014779:Virus Replication
D017503:Adenovirus E3 Proteins; D000914:Antibodies, Viral; D000956:Antigens, Viral; D006023:Glycoproteins; D009698:Nucleoproteins; D011819:Rabies Vaccines; D014614:Vaccines, Synthetic; D014759:Viral Envelope Proteins; C079096:adenovirus 5, rabies glycoprotein recombinant vaccine; C064951:glycoprotein G, Rabies virus